CSS LLC’s Accelerate Diagnostics AXDX Stock Holding History

CSS LLC’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20	Closed	-$3K	–	793
2020 Q2	$3K	Buy	+20	New	+$1.97K	﹤0.01%	641
2020 Q1	–	Sell	-650	Closed	-$110K	–	619
2019 Q4	$110K	Buy	+650	New	+$107K	0.01%	553

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

CSS LLC's AXDX Position: Q1 2023 in Review

CSS LLC sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 3,610 shares — an estimated $25.5K sold.

CSS LLC first reported a position in AXDX in Q4 2019 and held it in 13 quarters. The position peaked at $544K in Q2 2020. 67 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

CSS LLC reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
CSS LLC sold 3,610 Accelerate Diagnostics shares in Q1 2023, an estimated $25.5K.
CSS LLC first reported a position in Accelerate Diagnostics in Q4 2019 and held it in 13 quarters.
CSS LLC's Accelerate Diagnostics position peaked at $544K in Q2 2020.
67 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.